Additional file 1. Supplementary files: Table S1.

Additional file 1. Appendix 1.

Supplementary Material 1

Supplementary Material 3

Supplementary Material 1

Supplementary Material 3

Additional file 1.

Additional file 1.

A new set of quinoline and isatine derivatives were synthesized as antiangiogenic VEGFR-2 inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit VEGFR-2 was found to be strong with IC50 values in the range of 76.64–175.50 nM. To investigate the cytotoxicity and safety, all compounds were tested against a panel of four cancer cell lines (A549, Caco2, HepG2 and MDA) as well as two normal cell lines (Vero and...

Depending on the pharmacophoric characteristics of EGFR inhibitors, a new thieno[2,3-d]pyrimidine derivative has been developed. Firstly, the potential inhibitory effect of the designed compound against EGFR has been proven by docking experiments that showed correct binding modes and excellent binding energies of −98.44 and −88.00 kcal/mol, against EGFR wild-type and mutant type, respectively. Furthermore, MD simulations studies confirmed the precise energetic, conformational, and dynamic alterations that occurred after binding to EGFR. The correct binding was...

Supplementary Material 1

Additional file 1. HPLC chromatogram of ethanolic leaf extract of cannabis.

Additional file 1. Outcomes definition(s).

Additional file 1. Outcomes definition(s).

Additional file 1. HPLC chromatogram of ethanolic leaf extract of cannabis.

New nicotinamide derivatives 6, 7, 10, and 11 were designed and synthesised based on the essential features of the VEGFR-2 inhibitors. Compound 10 revealed the highest anti-proliferative activities with IC50 values of 15.4 and 9.8 µM against HCT-116 and HepG2, respectively compared to sorafenib (IC50 = 9.30 and 7.40 µM). Compound 7 owned promising cytotoxic activities with IC50 values of 15.7 and 15.5 µM against the same cell lines, respectively. Subsequently, the VEGFR-2 inhibitory activities...

Depending on the pharmacophoric characteristics of EGFR inhibitors, a new thieno[2,3-d]pyrimidine derivative has been developed. Firstly, the potential inhibitory effect of the designed compound against EGFR has been proven by docking experiments that showed correct binding modes and excellent binding energies of −98.44 and −88.00 kcal/mol, against EGFR wild-type and mutant type, respectively. Furthermore, MD simulations studies confirmed the precise energetic, conformational, and dynamic alterations that occurred after binding to EGFR. The correct binding was...

Respiratory tract infections are a common cause of morbidity and mortality globally. The current paper aims to treat this respiratory disorder. Therefore, we elucidated the phytochemical profile of Euphorbia milii flowers and isolated chlorogenic acid (CGA) for the first time. The electrospraying technique was utilized to prepare CGA nanoparticles in polyvinyl alcohol (PVA)/PLGA polymeric matrix. Complete in vitro characterizations were performed to determine particle size, polydispersity index (PDI), zeta potential, loading efficiency (LE), scanning electron...

A new set of quinoline and isatine derivatives were synthesized as antiangiogenic VEGFR-2 inhibitors. On a biological level, the in vitro ability of the obtained candidates to inhibit VEGFR-2 was found to be strong with IC50 values in the range of 76.64–175.50 nM. To investigate the cytotoxicity and safety, all compounds were tested against a panel of four cancer cell lines (A549, Caco2, HepG2 and MDA) as well as two normal cell lines (Vero and...

Supplemental material, sj-docx-1-jic-10.1177_08850666221150886 for Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study by Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Abdullah Al Harthi, Hisham A. Badreldin, Muath A. Alsalloum, Khalid Eljaaly, Aisha Alharbi, Rowina Aljehani, Ramesh Vishwakarma, Abeer A. Alenazi, Mai Alalawi, Abdulrahman Alissa, Kholoud Al Aamer, Huda Al Enazi, Mohammed Almusallam, Abdulaziz Alshehri, Rawan Bukhari, Ghaday Alasmari, Maha M. AlQahtani, Sultanah Al Shammari,...

Supplemental material, sj-docx-1-jic-10.1177_08850666221150886 for Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study by Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Abdullah Al Harthi, Hisham A. Badreldin, Muath A. Alsalloum, Khalid Eljaaly, Aisha Alharbi, Rowina Aljehani, Ramesh Vishwakarma, Abeer A. Alenazi, Mai Alalawi, Abdulrahman Alissa, Kholoud Al Aamer, Huda Al Enazi, Mohammed Almusallam, Abdulaziz Alshehri, Rawan Bukhari, Ghaday Alasmari, Maha M. AlQahtani, Sultanah Al Shammari,...

In agreement with the general features of VEGFR-2 inhibitors, a new naphthalene analog (compound 7) has been designed and synthesized. The inhibitory potential of compound 7 was indicated by the proper binding and the perfect energy of −21.10 kcal/mol compared to sorafenib (−21.22) in the molecular docking studies. Next, six MD simulation studies over 100 ns (RMSD, RMSF, SASA, RoG, hydrogen bonding, and distance between the center of mass) confirmed the accurate interaction of compound...

Additional file 1. Appendix 1.

Supplementary Material 1

Supplementary Material 2